Detalles de la búsqueda
1.
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
Anticancer Drugs
; 15(9): 835-41, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15457123
Resultados
1 -
1
de 1
1
Próxima >
>>